SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

35 Managed Care Status • Available as a prescription option to 207M covered lives • Broad coverage by a majority of managed care providers • Silenor ® benefits from strong Medicare Part D coverage, including preferred formulary status with Caremark / SilverScripts ; new Caremark / SilverScripts contract for 2017 results in improved G2N ($ in millions) Source: MMIT as of July 2018 (managed care chart). ( 1 ) Custom plans may vary. Formulary Status Silenor Top National Payers Commercial Formulary Status (1) Express Scripts T3 CVS Health Caremark T2 OptumRx/United HealthCare NC Aetna/Coventry T3-2ST; Performance Formulary - T2 Prime Therapeutics T3; Net Results A&F - NC (40% Lives) MedImpact T3-ST WellPoint/Anthem T3-ST CIGNA T3 (50% of lives) Kaiser Foundation Health Plans NC EnvisionRX T3 Humana NC Preferred , 16% Preferred (PA/ST) , 9% Covered , 31% Covered (PA/ST) , 33% Not Covered , 12% Managed Care Status